Influenza viruses
CSL Biotherapies, a leading manufacturer of thimerosal-free seasonal influenza vaccine, has initiated shipment of its seasonal influenza virus vaccine to U.S. distributors for the 2009-2010 season. The company plans to deliver over eight million doses of the vaccine, primarily in single-dose, thimerosal-free, pre-filled syringes. This early delivery demonstrates CSL
Swine influenza
Infectious diseases remain a significant cause of morbidity and mortality in patients with cancer, with the malignancy itself often predisposing patients to severe or recurrent infections. The National Comprehensive Cancer Network (NCCN) has recognized the importance of providing the latest information on treating these infections and has developed the NCCN
Swine influenza
Australian researchers at the North Melbourne WHO Collaborating Centre for Reference and Research on Influenza have discovered that the H1N1 flu virus has mutated into a form resistant to the antiviral drug Relenza. Although the mutation poses little threat to humans, the discovery highlights the potential for antiviral-resistant viruses to
Influenza viruses
CEL-SCI Corporation has announced the development of an immune-based treatment for the swine flu and related H1N1 viruses, utilizing its proprietary L.E.A.P.S.(TM) vaccine technology. The company aims to leverage its expertise in developing protective and therapeutic vaccines to create a therapeutic treatment for individuals infected
Influenza viruses
Virologists have discovered a crucial aspect of the influenza A virus's ability to attach and enter susceptible cells, with the precise amino acids in the hemagglutinin protein controlling sialic acid binding specificity and affinity varying among antigenic subtypes. Specifically, for H3 subtypes, amino acids 226 and 228 are
